Medical devices: post-market surveillance requirements

AI Summary

The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 represent a significant update to the regulatory framework for medical devices within Great Britain. This amendment updates the UK Medical Devices Regulations 2002 by introducing a dedicated section, Part 4A, focused on post-market surveillance. While this document does not target a specific company or detail individual inspection dates, it establishes mandatory safety standards for all manufacturers of medical devices, in vitro diagnostics, and active implantable devices. The primary focus of the regulation addresses the need for enhanced safety monitoring after a product has received market approval. Key requirements include the mandatory notification of incidents and the implementation of systematic preventive and corrective actions. Manufacturers are now required to establish formal processes to identify potential risks and address them through standardized reporting and remediation strategies. By tightening these requirements, the UK government aims to ensure continuous oversight of device performance and patient safety. To remain compliant, companies must update their internal quality systems to align with these new incident reporting timelines and proactive surveillance obligations. This regulatory shift moves the industry toward a more data-driven approach to safety management throughout the full lifecycle of medical technology.